Cretostimogene grenadenorepvec, an oncolytic immunotherapy, selectively replicates in and lyses cancer cells with Rb-E2F pathway alterations, releasing antigens that initiate antitumor immune ...

For Cohorts A and B, intravesical cretostimogene will be instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by ...

The first 24 patients who received treatment with cretostimogene and were evaluated for high-grade recurrence-free survival and safety were evaluated. Kaplan-Meier estimates at 3- and 9-month ...

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...

Oliver Sartor: Hi, I'm Oliver Sartor with Uro Today, covering metastatic castration resistant prostate cancer at ASCO 2025. A real delight for me to welcome Mark Stein, associate professor at Columbia ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a radioligand therapeutics proffered paper session. Dr. Karolien Goffin discussed the previously ...

KLK2 protein is overexpressed in prostate cancer tissue compared to benign prostate tissue and has been associated with stage ...

RENALuT is a phase 2, single-arm trial evaluating the efficacy of [177Lu]Lu-PSMA-617 in patients with second- or third-line metastatic clear cell renal cell carcinoma (ccRCC). The study explores a ...

Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma ...

Presented at ASCO 2021 by Dr. de Bono, gumelutamide (TAS3681) is a third generation androgen receptor antagonist targeting the ligand binding domain, but this agent also had minimal activity based on ...

Tarcan T, Drake MJ, Igawa Y, et al. Can we predict whether a man with acute or chronic urinary retention will void after bladder outflow resistance reduction surgery? ICI-RS 2023. Neurourol Urodyn.

Of testicular cancer survivors aged <30 years at diagnosis, 60% fathered a post-index child, compared to 73% of the controls ...